Almirall enters partnership with Inserm Transfert to research vitiligo

A partnership between the Spanish biotech firm and the private subsidy of French public research organization Inserm will focus on finding treatment options for the chronic skin condition vitiligo.
Photo: Mikkel Aabenhus Hemmingsen / MedWatch
Photo: Mikkel Aabenhus Hemmingsen / MedWatch
by andreas lønstrup, translated by daniel pedersen

Spanish skin health firm Almirall has entered a licensing and research collaboration with Inserm Transfers, a private subsidiary of Inserm, which is the French National Institute of the Health and Medical Research, the company reports in a press release.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading